Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.
Mesenchymal chondrosarcoma is a very rare disease that often has a lot of potential to metastasize, Chawla says.
In this small study of fewer than 20 patients, some patients had previously failed standard chemotherapy and trabectedin did control disease in some of those patients for up to two years.
Moving forward, Chawla says, there will first need to be collaboration between institutions and pharmaceutical companies to determine if similar results have been seen before.
Final Analysis of Niraparib Does Not Show Significant OS Benefit in Recurrent Ovarian Cancer
March 27th 2023In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.
Read More
Dual Checkpoint Blockade With Neoadjuvant Chemo Shows Benefit in Ovarian Cancer
March 27th 2023The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.
Read More
HRQOL Not Affected by Cytoreductive Surgery Plus HIPEC in Ovarian Cancer
March 26th 2023According to Vadim Gushchin, MD, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of how it may impact a patient’s health-related quality of life.
Read More
2 Clarke Drive
Cranbury, NJ 08512